The basket trial is a P2, which is to determine the best protocol for a P3 trial. I don't think the 350 or 525mg are failing to show results, it could be they want to see how much the impact is at each dose. The 700mg dose may have more occupancy but not necessary, or maybe the more occupancy the better - that is the point of the p2 trial. They are also looking at quite a few different indicators of what leronlimab is doing, could be they are learning if the dose has an impact on one indicator but maybe if the increased dose another indicator of action is showing up.